# Pembrolizumab And Lenvatinib In Leptomeningeal Metastases

> **NCT04729348** · PHASE2 · TERMINATED · sponsor: **Massachusetts General Hospital** · enrollment: 10 (actual)

## Conditions studied

- Solid Tumor
- Solid Tumor, Adult
- Leptomeningeal Metastasis

## Interventions

- **DRUG:** Pembrolizumab
- **DRUG:** Lenvatinib

## Key facts

- **NCT ID:** NCT04729348
- **Lead sponsor:** Massachusetts General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-03-08
- **Primary completion:** 2024-01-17
- **Final completion:** 2024-01-17
- **Target enrollment:** 10 (ACTUAL)
- **Why stopped:** Planned interim analysis
- **Last updated:** 2025-07-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04729348

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04729348, "Pembrolizumab And Lenvatinib In Leptomeningeal Metastases". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04729348. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*